Investment Trends in Early Stage BioPharma Report
This report covers:
- The total funding raised for Series A rounds in the last 6 years.
Trends in upfront licensing payments illustrating the continued faith in biologicals over advanced therapeutics. - The fluctuations in market activity, with Q1 2024 marking a significant resurgence in biopharma IPOs despite a quieter start in terms of overall deal numbers compared to the previous year.
- Additionally, we present a comparative study of the number and types of deals in Q1 2023 versus Q1 2024, offering a snapshot of the evolving investment landscape.
- Stay ahead of the curve and enhance your investment strategy with insights from our comprehensive report.
You May Also Be Interested In…
What is Beacon?
Beacon is a world leading data analysis tool for preclinical and clinical trial information. With unrivalled granularity of search function, data quality, and exhaustiveness, Beacon provides timely information and gives you confidence to progress your targeted drug therapies to patients.
Learn more about how our clinical trials and drug database solutions can be tailored to your research requirements
